| Literature DB >> 30815151 |
Boris Winterhoff1,2,3, Stefan Kommoss4, Florian Heitz5, Gottfried E Konecny6, Sean C Dowdy7, Sally A Mullany1, Tjoung-Won Park-Simon8, Klaus Baumann9, Felix Hilpert10, Sara Brucker4, Andreas du Bois5, Willibald Schröder11, Alexander Burges12, Steven Shen2, Jinhua Wang2,3, Roshan Tourani2, Sisi Ma2,13, Jacobus Pfisterer14, Constantin F Aliferis2,3,13.
Abstract
We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life. (c) Connecting development of precision medicine tests to Randomized Clinical Trials enhances the robustness of computational modeling, accelerates development and validation of the precision test by 5-10 years, is highly generalizable and scalable, and should thus be considered as a high-priority design for similar precision medicine efforts.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30815151 PMCID： PMC6371365
Source DB: PubMed Journal: AMIA Annu Symp Proc ISSN： 1559-4076